NUCC-390 dihydrochloride is selective agonist of small-molecule CXCR4 receptor.

NUCC-390 dihydrochloride (10 μM;?pre-treatment 30 mins) leads to increased levels of pERK, it has the capability of stimulating signaling activity downstream of CXCR4 receptors[1].NUCC-390 (10 μM;?2 hours) can induce CXCR4 receptor internalization, and non-treated cells exhibit some diffuse expression of CXCR4-YFP throughout the cytosol and clear expression in the cell membrane in HEK cells[1].

NUCC-390 dihydrochloride?contributes to the functional and anatomical recovery of the neuromuscular junction (NMJ) following an acute nerve terminal damage by α-LTx in CD-1 mice.

T12269L

C23H35Cl2N5O

468.46

NUCC-390 dihydrochloride

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years